ZyVersa Therapeutics, Inc. (ZVSA)
(Delayed Data from NSDQ)
$4.94 USD
+0.86 (21.08%)
Updated May 31, 2024 03:59 PM ET
After-Market: $5.00 +0.06 (1.21%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
ZyVersa Therapeutics, Inc. [ZVSA]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: ZyVersa Therapeutics, Inc.
Industry: Unclassified
4Q Recap; VAR 200 DKD Phase 2a Study Initiation On Target in 1H24; IC 100 to Enter the Clinic By YE24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ZyVersa Therapeutics, Inc.
Industry: Unclassified
NLRP3 Inflammasome Could Be a Potent Target For Obesity; Reduce PT to $12 on Dilution From Warrant Exercises; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ZyVersa Therapeutics, Inc.
Industry: Unclassified
Research Suggests Inflammasome Inhibition With IC 100 Could Ameliorate Systemic Inflammation in Obesity; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ZyVersa Therapeutics, Inc.
Industry: Unclassified
With Funding in Place, CRO Selected For Phase 2a Trial of VAR 200 in DKD; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ZyVersa Therapeutics, Inc.
Industry: Unclassified
1-for-35 Reverse Stock Split Becomes Effective; Adjusting PT to $24 on Financial Overhang
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ZyVersa Therapeutics, Inc.
Industry: Unclassified
3Q Recap: VAR 200 to Enter Proof-of-Concept DKD Study in 1Q24; IC 100 Also Close to Entering the Clinic; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: ZyVersa Therapeutics, Inc.
Industry: Unclassified
We initiate coverage with a Buy rating and $2.50 price target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
|